Bayer announced today that data from 13 new analyses from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the American College of Cardiology (ACC) 74th ...

Bayer's 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly. Read why BAYZF ...

The FDA accepts and grants priority review to BAYRY's sNDA for Kerendia to treat patients with a common form of heart failure ...

The US Food and Drug Administration (FDA) accepted and granted Priority Review designation for Bayer’s (BAYN: DE) supplemental new drug application (sNDA) for a new indication for Kerendia (finerenone ...

Healthcare companies rose as traders sought out sectors that are less vulnerable to swings in economic growth and inflation prospects.

Regulators are expected to make a decision in the third quarter of 2025 on Kerendia to treat patients with heart failure with ...

Berlin: Bayer has announced that the Company has received Priority Review designation from the U.S. Food and Drug ...

Bayer has won U.S. Food and Drug Administration priority review for its application seeking expanded approval of its kidney-disease drug Kerendia in certain people with heart failure.

Additionally, learners will have access to Avado's recently launched Mentor Programme. This initiative connects students with over 1,200 experienced HR mentors through Avado Connect, ensuring they ...

Pharmaceuticals grew by 2.4%, with new drugs Nubeqa (prostate cancer) and Kerendia (metabolic disease) posting strong adjusted growth of 73% and 62%, respectively, but partially offset by ...

Kerendia sales surged 62%, mainly due to a substantial rise in volumes in the United States and business expansion in China. However, sales of oral anticoagulant Xarelto, co-developed with J&J JNJ ...

The crops division continues to suffer from low commodity prices. The pharma unit needs cancer treatment Nubeqa and kidney medicine Kerendia to keep growing strongly to counteract the sales decline of ...